Robert C. Millonig, Ph.D.

Robert C. Millonig, Ph.D. is a director in Sterne Kessler’s Biotechnology & Chemical Practice Group. He has significant experience developing and analyzing complex multi-patent portfolios for marketed innovator and generic pharmaceutical products. His approach to resolving legal issues revolves around reaching the solution that best meets the client’s business needs, rendering more than 5,000 opinions in the pharmaceutical space alone. Bob counsels clients in various intellectual property matters including patent validity and infringement analysis, freedom to operate, patentability investigations and FDA/ANDA practice. He is versed in the interplay between FDA regulations and patent law and has successfully co-counseled on major litigation involving patent challenges.

Specifically, Bob has been involved in developing strategy for challenging patents on fexofenidine, alendronate, raloxifine and extended release niacin to name a few. He has also provided strategic and technical counsel for top companies such as Teva Pharmaceutical Industries Ltd. and Apotex.

Bob’s extensive pharmaceutical know-how and evaluations of paragraph IV challenges enable him to evaluate and bolster innovator patent holders’ portfolios by reviewing them from a unique generic perspective.

Bob’s technical experience is focused in the areas of biochemistry, molecular and cell biology, chemistry and pharmacology. He has extensive experience prosecuting United States patent applications and providing counsel in these areas.

Bob’s dissertation research relates to the structure and polymerization of the actin filament and involved electron microscopy as well as various protein chemistry techniques. While conducting his dissertation research, Bob spent three years at the Biozentrum of the University of Basel, Switzerland.